Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Thiosulfate for Otoprotection in Relapsed/Refractory Embryonal Tumors
NCT05756660Phase 1Suspended
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Mar 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sodium thiosulfate in ototoxicity (3 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Prevention of hearing loss at 5 years. Started Mar 2023; status: suspended.
02
Drugs
sodium thiosulfate
03
Conditions
ototoxicity
Beyond the preview
Go deeper on NCT05756660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05756660.